Latest Amylyx Pharmaceuticals News & Updates

See the latest news and media coverage for Amylyx. We track all announcements, press releases, and industry mentions in real time, all in one place.

Amylyx Pharmaceuticals (Amylyx)

Clinical-stage biopharmaceutical company developing therapies for serious diseases

amylyx.com

Headquarters: Cambridge, United States
Company type: Public company
Number of employees: 180–200
Industry: Pharmaceuticals

Last updated October 21

Latest news about Amylyx Pharmaceuticals (Amylyx)

In short: Amylyx reported positive Phase 3 avexitide LUCIDITY results in post-bariatric hypoglycemia, clearing the path to an FDA filing.

Company announcements

October 21 Amylyx

Amylyx celebrates LUCIDITY trial results

The company marks positive Phase 3 data with a gathering at its founding location, honoring contributors and focusing on future work.

August 19 Amylyx

Amylyx raises $500 million via public stock offering

The company plans to use proceeds for avexitide development, research and general purposes. The deal closes around August 21.

August 18 Amylyx

Amylyx announces $350 million public offering of common stock for R&D

The company intends to use proceeds for avexitide manufacturing and research. Underwriters include Leerink and Morgan Stanley with a 30-day option.

August 17 Amylyx

Amylyx announces Phase 3 LUCIDITY trial results

The update arrives August 18 during a live call analyzing avexitide efficacy for post-bariatric hypoglycemia.

Media coverage

October 2 Yahoo Finance

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the...

September 29 Investing.com

Amylyx at Stifel 2026 forum: avexitide advances in hypoglycemia

Amylyx indicated that the Phase 3 trial of avexitide met its primary endpoint with a 55% reduction in level 2 hypoglycemic events...

September 7 Gelbe Liste

Avexitide reduces hypoglycemia after bariatric surgery

Post-bariatric hypoglycemia is a burdensome complication following bariatric procedures. For this indication, which has not yet been approved, positive phase III data for the GLP-1 receptor...

August 18 The Globe and Mail

Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide

Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.

Never miss news about Amylyx

Track Amylyx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Amylyx competitors & trending companies

Browse news for competitors to Amylyx and other trending companies.